<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364013</url>
  </required_header>
  <id_info>
    <org_study_id>20050203</org_study_id>
    <nct_id>NCT00364013</nct_id>
  </id_info>
  <brief_title>PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy</brief_title>
  <official_title>A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the treatment effect of panitumumab in combination
      with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.</time_frame>
    <description>Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.</time_frame>
    <description>The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response</measure>
    <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
    <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
    <description>Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
    <description>Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.</time_frame>
    <description>A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: &quot;Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1183</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
    <other_name>Vectibix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.</description>
    <arm_group_label>FOLFOX + Panitumumab</arm_group_label>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman at least 18 years old

          -  Diagnosis of metastatic colorectal cancer

          -  At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Paraffin-embedded tumor tissue from the primary tumor or metastasis available for
             central analyse Exclusion Criteria:

          -  History or known presence of central nervous system (CNS) metastases

          -  History of another primary cancer, except: Curatively treated in situ cervical cancer,
             or Curatively resected non-melanoma skin cancer, or Other primary solid tumor
             curatively treated with no known active disease present and no treatment administered
             for ≥ 5 years before randomization

          -  Prior chemotherapy or systemic therapy for the treatment of metastatic colorectal
             carcinoma except: adjuvant fluoropyrimidine-based chemotherapy or prior
             fluoropyrimidine therapy administered solely for the purpose of radiosensitization

          -  Prior oxaliplatin therapy

          -  Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or
             treatment with small molecule EGFr inhibitors (eg, erlotinib)

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) 1 year prior to randomization History of interstitial lung disease (eg,
             pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on
             baseline chest computed tomography (CT) scan

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
             (defined as &gt; Common terminology criteria (CTC) grade 2 [CTCAE version 3.0])

          -  Peripheral sensory neuropathy with functional impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.</citation>
    <PMID>24024839</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014 Jul;25(7):1346-55. doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8.</citation>
    <PMID>24718886</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.</citation>
    <PMID>20921465</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Siena S, Peeters M, Koukakis R, Terwey JH, Tabernero J. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015 Jul;51(10):1231-42. doi: 10.1016/j.ejca.2015.03.026. Epub 2015 May 5.</citation>
    <PMID>25956209</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>February 13, 2014</results_first_submitted>
  <results_first_submitted_qc>February 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2014</results_first_posted>
  <disposition_first_submitted>July 20, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2010</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>EGFr</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Clinical Trail</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 23 August 2006 and last patient enrolled 01 February 2008.
Participant flow data are reported as of the data cut-off date of 28 August 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FOLFOX + Panitumumab</title>
          <description>Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>FOLFOX Alone</title>
          <description>Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="593"/>
                <participants group_id="P2" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="586">One participant randomized to this group did not receive any panitumumab</participants>
                <participants group_id="P2" count="583"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="492">Indicates participants who had completed the safety visit 30 days after last dose or had died</participants>
                <participants group_id="P2" count="495">Indicates participants who had completed the safety visit 30 days after last dose or had died</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOLFOX + Panitumumab</title>
          <description>Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>FOLFOX Alone</title>
          <description>Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="593"/>
            <count group_id="B2" value="590"/>
            <count group_id="B3" value="1183"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="10.1"/>
                    <measurement group_id="B2" value="60.3" spread="11.0"/>
                    <measurement group_id="B3" value="60.9" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="386"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="530"/>
                    <measurement group_id="B2" value="540"/>
                    <measurement group_id="B3" value="1070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic Region</title>
          <description>Stratification factor. Rest of world includes South America, eastern Europe, South Africa and Mexico</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Western Europe, Canada and Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of world</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KRAS Status</title>
          <description>KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wild-type KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutant KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt; 50% of waking hours; Grade 3: Capable of only limited self care, confined to a bed or chair &gt; 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5: Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mising/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary tumor type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colon cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
        <time_frame>From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.</time_frame>
        <population>KRAS Efficacy Analysis Set (participants for whom KRAS status was assessed)</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFOX</title>
            <description>Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFOX</title>
            <description>Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
          <population>KRAS Efficacy Analysis Set (participants for whom KRAS status was assessed)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="9.2" upper_limit="11.1"/>
                    <measurement group_id="O2" value="8.0" lower_limit="7.5" upper_limit="9.3"/>
                    <measurement group_id="O3" value="7.3" lower_limit="6.3" upper_limit="8.0"/>
                    <measurement group_id="O4" value="8.8" lower_limit="7.7" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PFS in the Wild-type KRAS Efficacy Analysis Set was compared at a significance level of 5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0234</p_value>
            <p_value_desc>P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).</p_value_desc>
            <method>Stratified log-rank test</method>
            <param_type>Normal score</param_type>
            <param_value>-2.27</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer progression-free survival time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PFS in the Mutant KRAS Efficacy Analysis Set was compared at a significance level of 5% conditional on first demonstrating a significant treatment effect in PFS in the Wild-type KRAS Efficacy Analysis Set.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0227</p_value>
            <p_value_desc>P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).</p_value_desc>
            <method>Stratified log-rank test</method>
            <param_type>Normal score</param_type>
            <param_value>2.28</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer progression-free survival time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.</description>
        <time_frame>From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.</time_frame>
        <population>KRAS Efficacy Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFOX</title>
            <description>Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFOX</title>
            <description>Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.</description>
          <population>KRAS Efficacy Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="20.3" upper_limit="28.3"/>
                    <measurement group_id="O2" value="19.7" lower_limit="17.6" upper_limit="22.6"/>
                    <measurement group_id="O3" value="15.5" lower_limit="13.1" upper_limit="17.6"/>
                    <measurement group_id="O4" value="19.3" lower_limit="16.5" upper_limit="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall survival comparisons in the wild-type KRAS Efficacy Analysis Set was performed at a significance level of 4.99% conditional on a statistically significant difference for PFS in the Wild-type KRAS Efficacy Analysis Set.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0723</p_value>
            <p_value_desc>cP-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).</p_value_desc>
            <method>Stratified log-rank test</method>
            <param_type>Normal score</param_type>
            <param_value>-1.80</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Overall survival comparisons in the mutant KRAS Efficacy Analysis Set was performed at an significance level of 4.99% conditional on a statistically significant difference for PFS in the Mutant KRAS Efficacy Analysis Set.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0678</p_value>
            <p_value_desc>P-value is based on a 2-sided log-rank test stratified by Region (Western Europe, Canada and Australia vs. Rest of World) and ECOG score (0 or 1 vs. 2).</p_value_desc>
            <method>Stratified log-rank test</method>
            <param_type>Normal score</param_type>
            <param_value>1.83</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the panitumumab plus FOLFOX arm and therefore a longer overall survival time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response</title>
        <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
        <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
        <population>KRAS Evaluable Central Tumor Response Analysis Set (subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review).</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFOX</title>
            <description>Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFOX</title>
            <description>Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response</title>
          <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
          <population>KRAS Evaluable Central Tumor Response Analysis Set (subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="323"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.21" lower_limit="49.55" upper_limit="60.77"/>
                    <measurement group_id="O2" value="47.68" lower_limit="42.12" upper_limit="53.28"/>
                    <measurement group_id="O3" value="39.53" lower_limit="32.95" upper_limit="46.41"/>
                    <measurement group_id="O4" value="40.28" lower_limit="33.61" upper_limit="47.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0684</p_value>
            <method>Stratified exact test</method>
            <method_desc>Adjusted for geographic region and ECOG score.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
            <estimate_desc>The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9822</p_value>
            <method>Stratified exact test</method>
            <method_desc>Adjusted for geographic region and ECOG score</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFOX alone arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.</description>
        <time_frame>From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
        <population>KRAS Efficacy Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFOX</title>
            <description>Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFOX</title>
            <description>Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.</description>
          <population>KRAS Efficacy Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="221"/>
                <count group_id="O4" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="9.4" upper_limit="12.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="7.7" upper_limit="9.9"/>
                    <measurement group_id="O3" value="7.5" lower_limit="7.2" upper_limit="8.9"/>
                    <measurement group_id="O4" value="9.0" lower_limit="7.7" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.</description>
        <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.</time_frame>
        <population>KRAS Evaluable Central Tumor Response Analysis Set: Responders</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFOX</title>
            <description>Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - FOLFOX + Panitumumab</title>
            <description>Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFOX</title>
            <description>Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.</description>
          <population>KRAS Evaluable Central Tumor Response Analysis Set: Responders</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="9.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="8.8" lower_limit="7.8" upper_limit="9.7"/>
                    <measurement group_id="O3" value="7.4" lower_limit="5.9" upper_limit="8.3"/>
                    <measurement group_id="O4" value="8.0" lower_limit="6.5" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: “Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
        <time_frame>From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.</time_frame>
        <population>Safety analysis set; One participant was randomized to 'Panitumumab Plus FOLFOX’, but received ‘FOLFOX Alone’ so is counted in that group.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFOX + Panitumumab</title>
            <description>Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>FOLFOX Alone</title>
            <description>Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: “Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
          <population>Safety analysis set; One participant was randomized to 'Panitumumab Plus FOLFOX’, but received ‘FOLFOX Alone’ so is counted in that group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="585"/>
                <count group_id="O2" value="584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583"/>
                    <measurement group_id="O2" value="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to discontinuation of any study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse event (TRAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581"/>
                    <measurement group_id="O2" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious treatment-related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAE leading to discontinuation of any study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm.</time_frame>
      <desc>One participant was randomized to 'Panitumumab Plus FOLFOX’, but received ‘FOLFOX Alone’ so is counted in that group.
The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panitumumab Plus FOLFOX</title>
          <description>Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>FOLFOX Alone</title>
          <description>Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperviscosity syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Faecalith</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Retroperitoneal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Inflammation of wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Acne pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Biliary abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Tumour local invasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="577" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="571" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="315" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="353" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="349" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="282" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="287" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="305" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="584"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="585"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

